semaglutide and cardiovascular disease Recent study at UC Irvine found that medication may benefit 93 million U.S. adults Evaluating the Cardiovascular Benefits of

Start Your weight Loss Journey With Expert Guidance Lipotropics or GLP-1s

Use a clean needle and syringe for each shot

Glucagon-like peptide-1 receptor agonists in peri-operative care Dispelling myths and unveiling insights with essential considerations for anaesthesiologists Larissa Paggers Dieter Mesotten Hendrik Stragier With the growing use of glucagon-like-peptide-1 (GLP-1) receptor (GLP-1R) agonists as anti-obesity medication it is becoming increasingly important to examine its consequences in the peri-operative period

There's also an active federal rulemaking worth understanding if you're weighing a compounded GLP-1 program in mid-2026: April 30, 2026 - FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that large-scale 503B outsourcing facilities may use to compound medications outside a declared drug shortage May 1, 2026 - proposal published in the Federal Register (91 Fed

FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with Type 2 diabetes, FDA (2024) FDA drug shortages, FDA (2024) Hikma receives FDA approval and launches the generic version of Victoza, Liraglutide, in the U.S., Hikma (2024) How Victoza works, Novo Nordisk Liraglutide injection, MedLinePlus (2021) Special report: Potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages, Clinical Diabetes (2023) Type 2 diabetes, CDC (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice